<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01813006</url>
  </required_header>
  <id_info>
    <org_study_id>2011/899(REK)</org_study_id>
    <secondary_id>2012-000505-68</secondary_id>
    <nct_id>NCT01813006</nct_id>
  </id_info>
  <brief_title>Effect of Omega-3 Fatty Acid on Endothelial Function</brief_title>
  <official_title>Effect of Omega-3 Polyunsaturated Fat on Endothelial Function and Inflammatory Parameters in Familial Hypercholesterolemia - a Double Blind, Placebo-controlled Crossover Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nordlandssykehuset HF</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pronova BioPharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Nordlandssykehuset HF</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background

      Familial hypercholesterolemia (FH) is an inherited disease in which the level of bad
      cholesterol (LDL-cholesterol) is increased, leading to an increase in coronary heart disease
      even if adequately treated with cholesterol lowering medication (statins). Polyunsaturated
      fatty acids (PUFA) including omega-3 is known to affect the risk for coronary disease,
      however its effect on patients with FH is not known.

      The purpose of the study is to assess the effect of PUFA on patients with FH, with regard to
      inflammation measured in the blood and the effect on the blood vessels`ability to relax
      (endothelial function) by means of tonometry.

      Hypothesis

      Treatment with 4 grams of PUFA a day for 4 months will lead to an improvement in the
      endothelial function, and the treatment will also lead to a decrease in in several markers of
      inflammation and in lipids in the blood.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reactive Hyperemia Index (RHI)</measure>
    <time_frame>Baseline</time_frame>
    <description>Reactive Hyperemia Index (RHI) is a measure for endothelial function by means of tonometry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reactive Hyperemia Index (RHI)</measure>
    <time_frame>3 months</time_frame>
    <description>Measure of endothelial function</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reactive Hyperemia Index (RHI)</measure>
    <time_frame>6 months</time_frame>
    <description>Measure of endothelial function</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reactive Hyperemia Index (RHI)</measure>
    <time_frame>9 months</time_frame>
    <description>Measure of endothelial function</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Markers of inflammation</measure>
    <time_frame>Baseline</time_frame>
    <description>Serological markers of inflammation including cytokines, C-reactive protein (CRP) and complement factors</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory markers</measure>
    <time_frame>3 months</time_frame>
    <description>Serological markers of inflammation including cytokines, CRP and complement factors</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory markers</measure>
    <time_frame>6 months</time_frame>
    <description>Serological markers of inflammation including cytokines, CRP and complement factors</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory markers</measure>
    <time_frame>9 months</time_frame>
    <description>Serological markers of inflammation including cytokines, CRP and complement factors</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Lipid parameters</measure>
    <time_frame>Baseline</time_frame>
    <description>Different fractions of lipids in the blood including LDL-cholesterol, HDL cholesterol, triglycerides and their subfractions</description>
  </other_outcome>
  <other_outcome>
    <measure>Lipid parameters</measure>
    <time_frame>3 months</time_frame>
    <description>Different fractions of lipids in the blood including LDL-cholesterol, HDL cholesterol, triglycerides and their subfractions</description>
  </other_outcome>
  <other_outcome>
    <measure>Lipid parameters</measure>
    <time_frame>6 months</time_frame>
    <description>Different fractions of lipids in the blood including LDL-cholesterol, HDL cholesterol, triglycerides and their subfractions</description>
  </other_outcome>
  <other_outcome>
    <measure>Lipid parameters</measure>
    <time_frame>9 months</time_frame>
    <description>Different fractions of lipids in the blood including LDL-cholesterol, HDL cholesterol, triglycerides and their subfractions</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Familial Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Omega-3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Omega-3 fatty acids</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo/olive oil</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omega-3</intervention_name>
    <arm_group_label>Omega-3</arm_group_label>
    <other_name>Omacor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>olive oil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  documented familial hypercholesterolemia

          -  age 18-60 years

          -  on statin treatment for at least 12 months

        Exclusion Criteria:

          -  pregnancy or planned pregnancy

          -  breast feeding

          -  cancer

          -  non-compliance

          -  PUFA/omega-3 &lt; 3 months before inclusion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Knut T Lappegård, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nordland Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Knut T Lappegård, MD, PhD</last_name>
    <phone>004775534000</phone>
    <email>knut.tore.lappegard@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anders W Hovland, MD, PhD</last_name>
    <phone>004775534000</phone>
    <email>anders.w.hovland@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Division of Internal Medicine, Nordland Hospital</name>
      <address>
        <city>Bodø</city>
        <zip>8011</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Knut T Lappegård, MD, PhD</last_name>
      <phone>004775534000</phone>
      <email>knut.tore.lappegard@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Anders W Hovland, MD, PhD</last_name>
      <phone>004775534000</phone>
      <email>anders.w.hovland@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Knut T Lappegård, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anders W Hovland, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 14, 2013</study_first_submitted>
  <study_first_submitted_qc>March 14, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2013</study_first_posted>
  <last_update_submitted>March 14, 2013</last_update_submitted>
  <last_update_submitted_qc>March 14, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Hyperlipoproteinemia Type II</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

